J&J Q2 2026: Revenue Rises 6.6% but Net Income Flat as Costs Climb

Johnson & Johnson (NYSE: JNJ) reported Q2 2026 worldwide sales of $25.31 billion, a 6.6% year-over-year increase, while adjusted EPS of $2.90 edged past the $2.87 consensus estimate. Despite the top-line growth, GAAP net income was essentially flat, slipping 0.1% to $5.53 billion, as faster-rising costs offset the revenue gain. Shares closed at $247.02 on Wednesday, July 15, falling 2.69% while the S&P 500 gained 0.40%.

Q2 2026 Results

• Worldwide revenue: $25.31 billion, up 6.6% year-over-year from $23.74 billion, with U.S. sales growing 7.3% to $14.53 billion and international sales rising 5.7% to $10.78 billion.
• Adjusted EPS: $2.90, beating the $2.87 consensus by approximately 1.0%; adjusted net earnings reached $7.08 billion, up 5.7% year-over-year.
• GAAP net income: $5.53 billion, essentially unchanged from $5.54 billion in Q2 2025, despite revenue growing $1.57 billion.
• Innovative Medicine segment: Worldwide sales of $16.38 billion, up 7.8% year-over-year, with U.S. sales growing 8.9% to $9.98 billion.
• MedTech segment: Worldwide sales of $8.93 billion, up 4.5% year-over-year, a slower pace that attracted investor attention per earnings call coverage.

What Drove the Results

Adjusted EPS of $2.90 beat the $2.87 consensus, and revenue of $25.31 billion grew 6.6% year-over-year. However, the company did not provide updated full-year EPS guidance figures in the data available, though the earnings call highlighted raised full-year guidance, according to Yahoo Finance coverage.

The core tension in the quarter was cost growth outpacing revenue growth. Selling, marketing and administrative expenses climbed 9.2% year-over-year to $6.43 billion from $5.89 billion, growing faster than the 6.6% revenue increase and compressing the GAAP operating margin by 0.6 percentage points to 26.7%. Other (income) expense, net, swung to a $331 million charge from $107 million in Q2 2025, a 209.3% increase year-over-year. The tax provision rose 27.1% to $1.21 billion from $954 million, further constraining the bottom line despite a gross margin that expanded modestly to 68.2% from 67.9%.

The Innovative Medicine segment drove the bulk of outperformance, with Spravato, J&J's depression treatment, posting stronger-than-expected second-quarter sales growth, according to Jefferies analysts cited in Yahoo Finance coverage. The MedTech segment, while growing 4.5% year-over-year, was flagged in coverage as a relative weak point, with Reuters reporting a MedTech miss that overshadowed the broader earnings beat.

Wall Street View

Jefferies cited Spravato's Q2 sales growth as a positive read-through for the psychedelic drug development space more broadly. Barron's reported that J&J's CFO characterized the guidance increase as a starting point rather than a ceiling. No new specific dollar price targets from named analyst firms were present in the available source data.

Investor Takeaway

The Q2 report illustrates a recurring dynamic at J&J: operational revenue growth, particularly within Innovative Medicine, is being partially absorbed by rising administrative costs and a higher tax burden, leaving GAAP net income growth lagging sales. The MedTech segment's 4.5% growth rate, while positive, trails the Innovative Medicine pace and warrants monitoring as a structural drag. Investors focused on bottom-line conversion will want to see whether J&J can moderate SG&A growth relative to revenue in the back half of 2026 to close the gap between top-line momentum and net income performance.